… Read: Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts … type natriuretic peptide (CNP) patents. However, excluding this concern … upside and diversification beyond BioMarin's guidance. … increasing competitive pressure on BioMarin's key …

… AGV) superior to placebo. BioMarin Pharmaceutical Inc’s BMRN stock … TransCon CNP is comparable to BioMarin’s Voxzogo (vosoritide), … of infringing on BioMarin’s long-acting CNP patent portfolio, which … result in royalties to BioMarin.” The William Blair analyst …

… everyday needs become very difficult. BioMarin estimates the incidence of CLN2 … brain (cerebrospinal fluid) using BioMarin's patented technology. Brineura, the first … European Commission. Founded in 1997, BioMarin is a global biotechnology company …

… cerebrospinal fluid) using BioMarin's patented technology. BRINEURA, … future events or otherwise. BioMarin®, BioMarin RareConnections® and BRINEURA® …                       Andrew Villani BioMarin Pharmaceutical Inc.  BioMarin Pharmaceutical Inc. (415) 455 …

… GlobalData’s company profile on BioMarin Pharmaceutical, Human telomerase RT … key innovation area identified from patents. BioMarin Pharmaceutical's grant … Patent and Trademark Office (USPTO). Credit: BioMarin Pharmaceutical Inc A recently granted patent …

… article highlighted the undervaluation of BioMarin Pharmaceutical (NASDAQ:BMRN), and the … to decline due to the patent expiration, its sales amounted to … be sufficient for regulatory approval. BioMarin is planning to present the …

… oncology’s hottest space. BioMarin appeases an activist Alexander … the new CEO of BioMarin Pharmaceutical, had an unenviable … that attract activist pressure, BioMarin actually makes money, and … GlaxoSmithKline pulls back inhaler patents after FTC warning letter …

… is challenging more than 100 patents on brand-name medicines … that listings for dozens of patents on such medicines as … to withdraw or amend their patent listings, or certify under … hemophilia. Analysts noted that BioMarin’s hard-to-manufacture therapies …

… take over as CEO of BioMarin Pharmaceuticals next month, inherits … point of relative weakness for BioMarin. The company recently scaled … that attract activist pressure, BioMarin actually makes money, and … over inaccurate or improper patent listings, STAT

… growth forecasts Mergers and acquisitions Patent trends Social media trends Timeline … companies Glossary Companies Mentioned Novartis BioMarin Bluebird bio Gilead Orchard Therapeutics …